Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome

Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in derma...

Descripción completa

Detalles Bibliográficos
Autores principales: Bossart, Simon, Seyed Jafari, S. Morteza, Heidemeyer, Kristine, Yan, Kexiang, Feldmeyer, Laurence, Borradori, Luca, Yawalkar, Nikhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050468/
https://www.ncbi.nlm.nih.gov/pubmed/37007766
http://dx.doi.org/10.3389/fmed.2023.1050230
_version_ 1785014656776011776
author Bossart, Simon
Seyed Jafari, S. Morteza
Heidemeyer, Kristine
Yan, Kexiang
Feldmeyer, Laurence
Borradori, Luca
Yawalkar, Nikhil
author_facet Bossart, Simon
Seyed Jafari, S. Morteza
Heidemeyer, Kristine
Yan, Kexiang
Feldmeyer, Laurence
Borradori, Luca
Yawalkar, Nikhil
author_sort Bossart, Simon
collection PubMed
description Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in dermal neutrophil number and expression of the pro-inflammatory cytokines IL-1β, IL-8, and IL-17 as assessed by immunohistochemical studies.
format Online
Article
Text
id pubmed-10050468
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100504682023-03-30 Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome Bossart, Simon Seyed Jafari, S. Morteza Heidemeyer, Kristine Yan, Kexiang Feldmeyer, Laurence Borradori, Luca Yawalkar, Nikhil Front Med (Lausanne) Medicine Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in dermal neutrophil number and expression of the pro-inflammatory cytokines IL-1β, IL-8, and IL-17 as assessed by immunohistochemical studies. Frontiers Media S.A. 2023-03-15 /pmc/articles/PMC10050468/ /pubmed/37007766 http://dx.doi.org/10.3389/fmed.2023.1050230 Text en Copyright © 2023 Bossart, Seyed Jafari, Heidemeyer, Yan, Feldmeyer, Borradori and Yawalkar. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Bossart, Simon
Seyed Jafari, S. Morteza
Heidemeyer, Kristine
Yan, Kexiang
Feldmeyer, Laurence
Borradori, Luca
Yawalkar, Nikhil
Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome
title Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome
title_full Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome
title_fullStr Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome
title_full_unstemmed Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome
title_short Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome
title_sort canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in schnitzler syndrome
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050468/
https://www.ncbi.nlm.nih.gov/pubmed/37007766
http://dx.doi.org/10.3389/fmed.2023.1050230
work_keys_str_mv AT bossartsimon canakinumableadstorapidreductionofneutrophilicinflammationandlonglastingresponseinschnitzlersyndrome
AT seyedjafarismorteza canakinumableadstorapidreductionofneutrophilicinflammationandlonglastingresponseinschnitzlersyndrome
AT heidemeyerkristine canakinumableadstorapidreductionofneutrophilicinflammationandlonglastingresponseinschnitzlersyndrome
AT yankexiang canakinumableadstorapidreductionofneutrophilicinflammationandlonglastingresponseinschnitzlersyndrome
AT feldmeyerlaurence canakinumableadstorapidreductionofneutrophilicinflammationandlonglastingresponseinschnitzlersyndrome
AT borradoriluca canakinumableadstorapidreductionofneutrophilicinflammationandlonglastingresponseinschnitzlersyndrome
AT yawalkarnikhil canakinumableadstorapidreductionofneutrophilicinflammationandlonglastingresponseinschnitzlersyndrome

Ejemplares similares